Obama’s Research Challenge

Obama wants to invest in science and technology, but a divided Congress and looming budget cuts could make it difficult to keep his promises.

Written byDan Cossins
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Wikimedia, HiperpatoIn the week following his re-election, US President Barack Obama reaffirmed his commitment to invest in scientific research. Obama said that one of the main aims of his administration would be to ensure that the US “is a global leader in research and technology and clean energy, which will attract new companies and high-wage jobs to America.” But a sharply divided Congress and the prospect of wide-ranging budget cuts resulting from the looming “fiscal cliff” present sizeable obstacles.

If the President fails to broker a deal with Congress to reduce the federal budget deficit by $1.2 trillion before January 2, 2013, automatic budget cuts kick in for federal agencies. The Office of Management and Budget estimates that most funding agencies would have their budgets cut by 8.2 percent. Universities and research agencies that receive grant money through such channels are bracing themselves. Claude Canizares, vice-president for research at Massachusetts Institute of Technology, told Nature that such cuts would mean a loss of $40 million for the university.

The cuts would also be damaging for biomedical research, as they would slash the National Institute for Health’s (NIH) budget by $2.5 billion. And as Ann Bonham, chief scientific officer at the Association of American Medical ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies